Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1...
Further diversifies Royalty Pharmaβs portfolio with market-leading respiratory therapyExpected to significantly...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to...
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.